NovaBay Pharmaceuticals News

With the launch of a global pivotal trial, NovaBay Pharmaceuticals has achieved a major development milestone in its efforts to commercialize an eye drop for the treatment of adenoviral conjunctivitis with its anti-infective aganocide, NVC-422. "What makes NVC-422 an attractive candidate is its broad spectrum of activity," Dr.

Shares of NovaBay Pharmaceuticals were cruising along for months in a price range pretty much centered at right around the $1.30 mark until a sudden slide took shape along as the general market started to experience an overall downturn.

EMERYVILLE, Calif., May 17, 2012 -- NovaBay Pharmaceuticals, Inc. , a clinical-stage biotechnology company developing novel anti-infective products for the treatment and prevention of topical infections, today announced that it has enrolled the first patients in its global Phase 2b clinical study.

NovaBay Pharmaceuticals is developing products that represent a microcosm of the Johnson & Johnsons, Strykers and Medtronics of the world -- non-discretionary healthcare items that will always be in demand, particularly given the swelling global population.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia EMERYVILLE, Calif., May 2, 2012 -- NovaBayA Pharmaceuticals, Inc.